Cancer vaccine market to hit $7B by 2015

Spurred by the recent approval of Dendreon's prostate cancer vaccine Provenge, a new report predicts that the cancer vaccine market will swell to a $7 billion industry by 2015. There are six types of vaccines in development, according to the report: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. Release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.